Correction: Efficacy and safety of anlotinib combined with chemotherapy in the treatment of metastatic triple negative breast cancer

Yeqiang Qian; Hefang Wu; Lu Gao

doi:10.22514/ejgo.2026.049

Article Menu

Export Article

Article Data

Views 172
Dowloads 125

This is a correction to: European Journal of Gynaecological Oncology. 2024; 45(3): 68-74. https://doi.org/10.22514/ejgo.2024.050

Corrections

Open Access

Correction: Efficacy and safety of anlotinib combined with chemotherapy in the treatment of metastatic triple negative breast cancer

Yeqiang Qian¹
Hefang Wu¹
Lu Gao^1,*,

¹Department of Oncology, Zongyang County Peopleʼs Hospital, 246700 Tongling, Anhui, China

DOI: 10.22514/ejgo.2026.049 Vol.47,Issue 3,October 2026 pp.151-152

Published: 15 October 2026

*Corresponding Author(s): Lu Gao E-mail: lu_gao1226@163.com

PDF (252.66 kB) View Full-text

Cite and Share

Yeqiang Qian, Hefang Wu, Lu Gao. Correction: Efficacy and safety of anlotinib combined with chemotherapy in the treatment of metastatic triple negative breast cancer. European Journal of Gynaecological Oncology. 2026; 47(3): 151-152. doi: 10.22514/ejgo.2026.049

URL:

https://www.ejgo.net/articles/10.22514/ejgo.2026.049

References

[1] Qian YQ, Wu HF, Gao L. Efficacy and safety of anlotinib combined with chemotherapy in the treatment of metastatic triple negative breast cancer. European Journal of Gynaecological Oncology. 2024; 45: 68–74.